Last updated: February 14, 2026
Market Overview and Price Projections for NDC 69367-0308
What is the drug associated with NDC 69367-0308?
NDC 69367-0308 corresponds to Inotuzumab Ozogamicin (Besponsa), a monoclonal antibody-drug conjugate indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
What is the current market landscape?
Market size and demand drivers:
- Incidence: Approximately 6,000 new cases of ALL annually in the U.S. (per CDC).
- Treatment landscape: Prior to Inotuzumab, options included chemotherapy and hematopoietic stem cell transplantation. The drug is among targeted therapies, offering an alternative for patients with relapsed/refractory disease.
- Competitors: Blinatumomab (Blincyto), a bispecific T-cell engager, is the primary competitor. Both target CD19-positive B-cell malignancies.
Market adoption:
- Post-approval (August 2017), adoption has increased as clinicians gain familiarity.
- Utilized in second-line therapy, often in combination with chemotherapy, or as a standalone in relapsed settings.
Regulatory status:
- FDA approval granted for adults with relapsed/refractory CD19-positive B-cell precursor ALL.
- EMA approval and other international approvals are limited or pending.
How does pricing compare to competitors?
| Drug |
Price per treatment course (approximate) |
Notes |
| Inotuzumab Ozogamicin |
$23,000 - $30,000 |
Based on wholesale acquisition cost (WAC), varies by dose and regimen. |
| Blinatumomab |
$75,000 - $100,000 |
Due to longer infusion times and dosing complexity. |
Note: Actual prices depend on dose, treatment duration, patient-specific factors, and negotiation with payers.
What are the price projections?
Near-term (next 2-3 years):
- Stable pricing is expected as patent protections remain intact until approximately 2028.
- Reimbursement landscape remains challenging, with payers scrutinizing high-cost therapies for relapsed/refractory ALL.
Long-term (beyond 2025):
- Biosimilar entry: No biosimilars currently approved; biosimilar development unlikely before 2028.
- Pricing pressure: May emerge if new therapies or combination treatments demonstrate superior efficacy or safety.
- Market expansion: Limited to indications in ALL; potential off-label use in other CD19-positive malignancies could influence demand and pricing modestly.
What are the key factors influencing future pricing?
- Patent exclusivity until 2028; biosimilar competition could drive prices down thereafter.
- Regulatory decisions on additional indications could expand market size.
- Clinical trial outcomes affecting perceived value and reimbursement levels.
- Market competition from emerging therapies, especially CAR-T cells targeting CD19 (e.g., Kymriah, Yescarta), which could impact demand dynamics.
What is the outlook for market growth?
- The relapsed/refractory ALL segment is projected to grow modestly at a compound annual growth rate (CAGR) of 3-5% over the next five years, driven by improved survival rates and expanding indications.
- Market penetration remains limited due to the narrow patient population and high treatment costs.
Key Takeaways
- The drug (Inotuzumab Ozogamicin) occupies a niche in relapsed/refractory ALL, with limited direct competitors.
- Pricing remains high (~$23,000–$30,000 per treatment cycle), with stability expected until biosimilar entry around 2028.
- Future price reductions are unlikely before patent expiry, unless driven by new competitors or healthcare policy shifts.
- Market growth is slow but steady, constrained by the small patient population and high treatment costs.
FAQs
1. How does the price of Inotuzumab Ozogamicin compare to its main competitor?
It costs about one-third to one-half of Blinatumomab, reflecting differences in manufacturing costs and complexity of administration.
2. When will biosimilars potentially impact the market?
Biosimilar competitors are unlikely before 2028, given patent protections and regulatory pathways.
3. Are price reductions expected in the near term?
Not significantly; prices are expected to remain stable unless mandated by payer policies or new competing therapies.
4. What factors could influence demand for this drug?
Regulatory approval for additional indications, clinician prescribing habits, and the development of competing therapies like CAR-T cells.
5. How does market adoption vary globally?
Adoption is highest in the U.S., with limited availability in other regions pending regulatory approvals.
References
- Centers for Disease Control and Prevention (CDC). 2021. "Leukemia Statistics."
- Food and Drug Administration (FDA). 2017. "Approval Letter for Inotuzumab Ozogamicin (Besponsa)."
- Evaluate Pharma. 2022. "Oncology and Hematology Drug Pricing Insights."
- IQVIA. 2022. "Market Dynamics in Hematologic Malignancies."
